ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study
Annals of Oncology
◽
10.1093/annonc/mdz157.007
◽
2019
◽
Vol 30
◽
pp. iv124
Author(s):
M. Saleh
◽
P. Cassier
◽
L. Eberst
◽
G. Naik
◽
V. Morris II
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Phase 1 Study
◽
Previously Treated
Download Full-text
Related Documents
Cited By
References
Safety and activity of ziv-aflibercept in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with colorectal cancer previously treated with irinotecan: Results from a phase 1 study.
Journal of Clinical Oncology
◽
10.1200/jco.2014.32.15_suppl.e14510
◽
2014
◽
Vol 32
(15_suppl)
◽
pp. e14510-e14510
Author(s):
Eric Van Cutsem
◽
David Khayat
◽
Chris Verslype
◽
Bertrand Billemont
◽
Sabine Tejpar
◽
...
Keyword(s):
Colorectal Cancer
◽
Phase 1
◽
Phase 1 Study
◽
Previously Treated
Download Full-text
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer
Investigational New Drugs
◽
10.1007/s10637-013-0056-3
◽
2013
◽
Vol 32
(3)
◽
pp. 473-480
◽
Cited By ~ 13
Author(s):
Yoshito Komatsu
◽
Takayuki Yoshino
◽
Kentaro Yamazaki
◽
Satoshi Yuki
◽
Nozomu Machida
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Peroxisome Proliferator
◽
Second Line
◽
Second Line Therapy
◽
Phase 1 Study
◽
Peroxisome Proliferator Activated Receptor
◽
Line Therapy
Download Full-text
A Phase 1 Study of Enadenotucirev, an Oncolytic Ad11/Ad3 Chimeric Group B Adenovirus, Administered Intravenously - Analysis of Dose Expansion and Repeat Cycle Cohorts in Patients with Metastatic Colorectal Cancer (Mcrc)
Annals of Oncology
◽
10.1093/annonc/mdu342.17
◽
2014
◽
Vol 25
◽
pp. iv367
◽
Cited By ~ 5
Author(s):
E. Calvo
◽
M. Gil Martín
◽
A. Cubillo
◽
J. Machiels
◽
S. Rottey
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Phase 1 Study
◽
Group B
Download Full-text
Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer
Cancer Science
◽
10.1111/cas.13227
◽
2017
◽
Vol 108
(5)
◽
pp. 1013-1021
◽
Cited By ~ 6
Author(s):
Hiroya Taniguchi
◽
Satoru Iwasa
◽
Kentaro Yamazaki
◽
Takayuki Yoshino
◽
Chika Kiryu
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Peptide Vaccine
◽
Phase 1 Study
◽
Peptide Epitopes
Download Full-text
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.
Journal of Clinical Oncology
◽
10.1200/jco.2014.32.15_suppl.3551
◽
2014
◽
Vol 32
(15_suppl)
◽
pp. 3551-3551
Author(s):
Guillem Argilés
◽
Rodrigo Dienstmann
◽
Marta Benavent Viñuales
◽
Andres Cervantes
◽
Susana Rosello Keranen
◽
...
Keyword(s):
Colorectal Cancer
◽
Monoclonal Antibody
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Phase 1 Study
Download Full-text
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Cancer Chemotherapy and Pharmacology
◽
10.1007/s00280-015-2850-4
◽
2015
◽
Vol 76
(5)
◽
pp. 925-932
◽
Cited By ~ 27
Author(s):
Johanna C. Bendell
◽
Lee S. Rosen
◽
Robert J. Mayer
◽
Jonathan W. Goldman
◽
Jeffrey R. Infante
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Phase 1 Study
Download Full-text
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Investigational New Drugs
◽
10.1007/s10637-021-01110-9
◽
2021
◽
Author(s):
Hyehyun Jeong
◽
Yong Sang Hong
◽
Jeong Eun Kim
◽
Hyeong-Seok Lim
◽
Joong Bae Ahn
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Dose Escalation
◽
Phase 1
◽
Vascular Disrupting Agent
◽
Safety And Efficacy
◽
Previously Treated
◽
Vascular Disrupting
Download Full-text
Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study
Annals of Oncology
◽
10.1093/annonc/mdu333.38
◽
2014
◽
Vol 25
◽
pp. iv182
◽
Cited By ~ 18
Author(s):
C.A. Gomez-Roca
◽
J. Delord
◽
C. Robert
◽
M. Hidalgo
◽
R. von Moos
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Braf Inhibitor
◽
Braf V600e
◽
Open Label
◽
Phase 1 Study
◽
Open Label Phase
Download Full-text
Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Cancer Chemotherapy and Pharmacology
◽
10.1007/s00280-015-2890-9
◽
2015
◽
Vol 77
(2)
◽
pp. 439-439
Author(s):
Johanna C. Bendell
◽
Lee S. Rosen
◽
Robert J. Mayer
◽
Jonathan W. Goldman
◽
Jeffrey R. Infante
◽
...
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Phase 1
◽
Phase 1 Study
Download Full-text
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
Case Medical Research
◽
10.31525/ct1-nct03880877
◽
2019
◽
Author(s):
Keyword(s):
Colorectal Cancer
◽
Metastatic Colorectal Cancer
◽
Previously Treated
◽
Irinotecan Dose
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close